Welcome to our dedicated page for Cresco Labs news (Ticker: CRLBF), a resource for investors and traders seeking the latest updates and insights on Cresco Labs stock.
Cresco Labs Inc. reports developments in branded cannabis products, retail dispensaries, cultivation, production and state-regulated market access. The company operates Sunnyside dispensaries and distributes cannabis brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi.
Recurring updates cover quarterly financial results, dispensary openings, medical and adult-use market activity, cannabis licensing matters and operational growth initiatives. Company communications also address branded product distribution, retail execution, balance sheet and cash-flow themes, community outreach, workforce development and legislative or regulatory engagement in the cannabis industry.
Cresco Labs (CRLBF) closed the acquisition of 100% of PharmaCann Penn, LLC for an aggregate consideration of US$50 million, adding nine operational medical marijuana dispensaries in Pennsylvania.
The acquisition expands Cresco’s retail footprint in the state, which generated more than US$1.1 billion in medical marijuana sales last year. Following closing, Cresco becomes the #1 retailer serving medical marijuana patients across Pennsylvania and already holds the #1 wholesaler position there. The company highlights that scale and vertical integration in this core market create durable competitive advantages and allow better leverage of its existing cultivation and wholesale infrastructure.
The US$50,000,000 purchase price is satisfied through a mix of cash and a seller note, and the transaction closed on a cash-free, debt-free basis with a normalized target level of working capital. The transaction is expected by Cresco to be immediately accretive to revenue, margins and cash flow, and this announcement is designated as a “designated news release” under Cresco’s January 29, 2026 prospectus supplement.
Cresco Labs (OTCQX: CRLBF) reported second quarter 2026 revenue of $173.3 million, gross profit of $86.9 million (50.2% margin) and adjusted gross profit of $89.5 million (51.6% margin). SG&A was $63.2 million, with adjusted SG&A of $55.4 million, or 32.0% of revenue.
The company generated net income of $15.4 million and adjusted EBITDA of $39.5 million, a 22.8% margin. Management highlighted sequential revenue growth of 15% and adjusted EBITDA growth of 20%. As of June 30, 2026, Cresco held $67 million in cash, with a $311 million senior secured term loan and $19 million mortgage. The company reported maintaining the No. 1 share position in several billion‑dollar markets and announced a CFO transition, with Sharon Schuler stepping down and Mark Stortz serving as interim CFO.
Cresco Labs (OTCQX:CRLBF) announced it will release its financial results for the quarter ended June 30, 2026 on Thursday, August 6, 2026, before the market opens. Management will host a 8:30 a.m. ET conference call and webcast, with the webcast archived for one year on the company’s investor relations website.
Cresco Labs (OTCQX: CRLBF) closed a US$50 million revolving credit facility with Massachusetts-based Needham Bank. The Facility bears a fixed 7.99% annual interest rate and matures in August 2030.
According to Cresco Labs, funds may support growth initiatives, acquisitions and general corporate purposes, providing non-dilutive capital and broader commercial banking services.
Cresco Labs (OTCQX: CRLBF) registered certain state-licensed medical cannabis facilities with the U.S. DEA after federal rescheduling of medical cannabis to Schedule III. The registrations cover dispensary, cultivation and processing operations serving medical patients within its footprint and use the expedited 60-day DEA registration pathway.
Cresco Labs (OTCQX: CRLBF) reported that the Texas Department of Public Safety corrected its conditional license tabulation under the Texas Compassionate Use Program, affecting multiple applicants. The conditional license previously awarded to Cresco Labs Texas, LLC has been rescinded, and the entity is now on the TCUP eligibility list.
Cresco Labs remains confident in its application, is evaluating options to work with the state, and is eligible for a conditional license if any of the 12 current conditional licensees fail due diligence or operational requirements.
Cresco Labs (OTCQX: CRLBF) reported Q1 2026 revenue of $151 million, gross profit of $75 million and Adjusted gross profit of $77 million (Adjusted gross margin 50.7%). SG&A was $54 million (36.0% of revenue); Adjusted SG&A was $51 million (33.7%). Net loss was $17 million; Adjusted EBITDA was $33 million (Adjusted EBITDA margin 21.7%).
As of March 31, 2026, cash and equivalents were $67 million; senior secured term loan was $310 million and mortgage loan $19 million. Subsequent items include conditional Texas medical license award, nine PA dispensary management openings, and two Ohio dispensary openings.
Cresco Labs (OTCQX: CRLBF) opened Sunnyside Aberdeen in Aberdeen, Ohio on May 5, 2026. This is the company’s second Ohio dispensary opened within a month, bringing Cresco Labs to 8 locations in Ohio and 74 locations nationally. Store hours are 9 a.m.–9 p.m.; pickup available at www.sunnyside.shop.
Cresco Labs (OTCQX:CRLBF) will report first quarter 2026 financial results on Friday, May 8, 2026 before the market opens. The company will host an earnings conference call and webcast at 8:30 am ET. Archived webcast access will be available for one year on the investor relations website.
Cresco Labs (OTCQX: CRLBF) opened Sunnyside Bridgeport at 435 Main Street, Bridgeport, Ohio on April 10, 2026. It is Cresco Labs' seventh dispensary in Ohio and its 73rd across the U.S.
The store is open daily 9 a.m.–9 p.m., sells Cresco Labs brands including Cresco, Supply, Good News, Mindy’s and Wonder, and offers online ordering for pickup at www.sunnyside.shop.